Effect of Low Dose of Colchicine on Platelet Reactivity
NCT ID: NCT05956145
Last Updated: 2025-01-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
80 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-06-17
Study Completion Date
2024-04-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Inflammation plays an important role in atherosclerosis and the occurrence of ischemic events. Statins, in addition to their lipid-lowering effect, have also documented anti-inflammatory effect that may partly explain their clinical benefit in reducing cardiovascular ischemic events. Colchicine is an orally administered anti-inflammatory drug that has been used for centuries in several anti-inflammatory or autoimmune diseases. Its mechanism of action occurs by the inhibition of tubulin polymerization and the generation of microtubules and by effects on cell adhesion molecules and inflammatory chemokines. However, there are no studies evaluating the in vivo "antiplatelet action" of colchicine in patients with established cardiovascular disease.
We will evaluate the effect of low-dose 0.5 mg QD colchicine for 30 ± 3 days on platelet reactivity by MultiplateTRAP.
Patients with proven chronic coronary artery disease, that is, documented previous myocardial infarction, will be randomized to receive colchicine 0.5 mg QD or placebo for a period of 30 ± 3 days.
We will evaluate the effect of low-dose 0.5 mg QD colchicine for 30 ± 3 days on platelet reactivity by MultiplateTRAP.
Patients with proven chronic coronary artery disease, that is, documented previous myocardial infarction, will be randomized to receive colchicine 0.5 mg QD or placebo for a period of 30 ± 3 days.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Colchicine on Platelet Function Profiles in Patients With Stable Coronary Artery Disease
NCT06567678
Coronary Artery Disease
COMPLETED
PHASE1
The Effect on Blood Cells, Known as Platelets, Using Prasugrel vs Clopidogrel in Patients With the Heart Problem Acute Coronary Syndrome (ACS)
NCT00385944
Acute Coronary Syndrome
COMPLETED
PHASE2
Anti-platelet Effects of Colchicine in Healthy Volunteers
NCT02140372
Healthy
COMPLETED
PHASE4
Effects of Edoxaban on Platelet Aggregation
NCT05122455
SCAD
AMI
COMPLETED
PHASE2/PHASE3
Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention
NCT00404781
Ischemic Heart Disease
Acute Coronary Syndromes
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inflammation plays an important role in atherosclerosis and the occurrence of ischemic events. Statins, in addition to their lipid-lowering effect, have also documented an anti-inflammatory effect that may partly explain their clinical benefit in reducing cardiovascular ischemic events. More recently, canaquinumab, a monoclonal anti-interleukin 1β antibody, significantly reduced vascular events in patients after acute myocardial infarction with residual inflammation, but failed to demonstrate progression to diabetes, including in patients with pre-diabetes. On the other hand, methotrexate has not been shown to be effective in reducing events in a similar population.
In addition to inflammation, thrombosis is directly involved in the pathogenesis of unstable ischemic syndromes. In this context, the association between greater platelet aggregability and clinical events is well established in the literature. The POPULAR study evaluated that after a 1-year follow-up, the primary outcome of death, non-fatal acute myocardial infarction, stent thrombosis or ischemic stroke occurred more frequently in patients with high platelet reactivity undergoing treatment with antiaggregants when evaluated by optical aggregometry and other point of care tests. Another study that evaluated the importance of the platelet response to medications was the ADAPT-DES, in which post-angioplasty patients on dual antiplatelet therapy were at higher risk of complications, especially stent thrombosis, when they presented with high platelet reactivity to clopidogrel. Both studies show the importance of the interaction between platelet changes and the medications that interact in this way and cardiovascular outcomes.
Colchicine is an orally administered anti-inflammatory drug that was initially extracted from autumn saffron and has been used for centuries in various diseases of an anti-inflammatory / autoimmune nature. Its bioavailability after oral administration takes place via uptake in the jejunum and ileum, its lipophilic nature allows it to be absorbed quickly by various types of cells. Its mechanism of action occurs through the inhibition of tubulin polymerization and the generation of microtubules and, possibly, effects on cell adhesion molecules and inflammatory chemokines.
Another route related to colchicine is the suppression of interleukin 1. It is able to prevent the intracellular assembly of the cytosolic protein complex NACHT-LRRPYD 3, responsible for the proteolytic cleavage of caspase-1, which breaks down and activates interleukin 1, blocking its maturation and secretion.
In addition to the action on inflammation, colchicine may be involved in reducing platelet aggregation, as suggested in a mechanistic study that evaluated the in vitro action of colchicine on platelet aggregation in healthy individuals. In this study, in addition to demonstrating the lower aggregability by electrical impedance in the sample subjected to colchicine action, it was found that the drug also exerted effects via inhibition of key proteins involved in the rearrangement of the platelet cytoskeleton. To the best of our knowledge, however, there are no studies evaluating the in vivo "antiplatelet action" of colchicine in patients with established cardiovascular disease.
In the population with coronary heart disease, two important randomized clinical studies have demonstrated the benefit of colchicine: 1) LoDoCo, which demonstrated a reduction in cardiovascular events (composed of infarction, unstable angina, cardiorespiratory arrest or stroke) with a low dose of colchicine in patients with stable coronary disease. ; 2) COLCOT showed a reduction in events, the composite of cardiovascular death, infarction, unstable angina, resuscitated cardiopulmonary arrest or stroke, in patients treated with colchicine after AMI.
Despite the cardiovascular benefit demonstrated in high-risk patients, little is known about the pathophysiological mechanisms involved, being the subject of debates about whether the observed results would be related to the reduction of the progression of atheroscletotic disease, to an antiplatelet effect, or both.
Primary objective: To evaluate the effect of colchicine in low dose for 30 ± 3 days on platelet aggregation by MultiplateTRAP.
Secondary objectives Evaluate the primary objective of the study using Multiplate ADP, ASPI and Collagen.
Exploratory Analysis
Comparison between the colchicine and placebo groups at the end of the 30 ± 3-day follow-up of the following parameters:
* Ultra-sensitive reactive C protein (hs-CRP);
* Interleukin 6 (IL-6);
* Interleukin 1 (IL-1);
* Serum Tromboxane B2;
* Count and fraction of reticulated platelets;
* Mean platelet volume (MPV);
* Total cholesterol / HDL / LDL / triglycerides, apolipoprotein A1, apolipoprotein B;
* Analysis of vascular reactivity;
* Transfer of lipids to HDL.
Analyze the primary outcome of the study in the following subgroups:
* Female versus male;
* Age group ( equal or major to 65 years);
* Presence or not of diabetes mellitus (characterized by use of hypoglycemic drugs previously and / or exam prior to randomization with HbA1c equal or minor to 6.5%);
* LVEF equal or major 40%;
* Obese versus non-obese (BMI equal or major 30)
* Smoker versus non-smoker
* median LDL
* PCRus equal or major 2mg / dl
Study design: Prospective, randomized, double-blind, placebo-controlled study. Patients with proven chronic coronary artery disease, documented by previous history of AMI, will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days. Randomization will be performed in 2 blocks of 40 patients at a rate of 1: 1. Blood samples will be obtained at the baseline visit and at the end-of-follow-up visit (30 ± 3days after the baseline visit).
Inclusion criteria: Agreement to sign a free and informed consent form; age ≥ 18 years; patients with previous acute myocardial infarction (or more than 1 year according to the criteria of the 4th universal definition using ASA 100mg / day.
Exclusion criteria: Use of any antithrombotic therapy other than AAS for less than 1 week; Stroke in the last 3 months; active infection or current use of systemic antimicrobial therapy; neoplasia in the last 3 years; inflammatory bowel disease or chronic diarrhea; hematological abnormality (Hb ≤ 11g / dL or\> 17g / dL, leukocytes ≤ 4,500 / mm3 or\> 11,000 / mm3, platelet count \<150,000 / mm3 or\> 450,000 / mm3); chronic kidney disease (estimated glomerular filtration rate \<30 ml / min / 1.73 m2) using the MDRD formula; liver disease defined by CHILD B or C; drug or alcohol abuse; dementia, psychiatric or any condition that, in the researcher's opinion, prevents participation and follow-up in the protocol; history of allergy to colchicine; current treatment with systemic corticosteroids or immunosuppressants.
Sample calculation: In a prior study, published in 2020, it was found an average platelet aggregability by Multiplate-TRAP in patients with chronic coronary disease of 102 AUC +/- 26. Another study analyzing platelet aggregation in vitro in healthy volunteers, found a reduction in aggregability by ADP by 40%. In the present study, for a hypothesis of superiority with a 20% reduction in the mean platelet aggregation in favor of colchicine over placebo, considering an alpha = 0.05 (two-tailed) and a power = 90%, the calculated sample size is 70 patients (35 per group), with a total of 80 being included to compensate for possible losses.
In addition to inflammation, thrombosis is directly involved in the pathogenesis of unstable ischemic syndromes. In this context, the association between greater platelet aggregability and clinical events is well established in the literature. The POPULAR study evaluated that after a 1-year follow-up, the primary outcome of death, non-fatal acute myocardial infarction, stent thrombosis or ischemic stroke occurred more frequently in patients with high platelet reactivity undergoing treatment with antiaggregants when evaluated by optical aggregometry and other point of care tests. Another study that evaluated the importance of the platelet response to medications was the ADAPT-DES, in which post-angioplasty patients on dual antiplatelet therapy were at higher risk of complications, especially stent thrombosis, when they presented with high platelet reactivity to clopidogrel. Both studies show the importance of the interaction between platelet changes and the medications that interact in this way and cardiovascular outcomes.
Colchicine is an orally administered anti-inflammatory drug that was initially extracted from autumn saffron and has been used for centuries in various diseases of an anti-inflammatory / autoimmune nature. Its bioavailability after oral administration takes place via uptake in the jejunum and ileum, its lipophilic nature allows it to be absorbed quickly by various types of cells. Its mechanism of action occurs through the inhibition of tubulin polymerization and the generation of microtubules and, possibly, effects on cell adhesion molecules and inflammatory chemokines.
Another route related to colchicine is the suppression of interleukin 1. It is able to prevent the intracellular assembly of the cytosolic protein complex NACHT-LRRPYD 3, responsible for the proteolytic cleavage of caspase-1, which breaks down and activates interleukin 1, blocking its maturation and secretion.
In addition to the action on inflammation, colchicine may be involved in reducing platelet aggregation, as suggested in a mechanistic study that evaluated the in vitro action of colchicine on platelet aggregation in healthy individuals. In this study, in addition to demonstrating the lower aggregability by electrical impedance in the sample subjected to colchicine action, it was found that the drug also exerted effects via inhibition of key proteins involved in the rearrangement of the platelet cytoskeleton. To the best of our knowledge, however, there are no studies evaluating the in vivo "antiplatelet action" of colchicine in patients with established cardiovascular disease.
In the population with coronary heart disease, two important randomized clinical studies have demonstrated the benefit of colchicine: 1) LoDoCo, which demonstrated a reduction in cardiovascular events (composed of infarction, unstable angina, cardiorespiratory arrest or stroke) with a low dose of colchicine in patients with stable coronary disease. ; 2) COLCOT showed a reduction in events, the composite of cardiovascular death, infarction, unstable angina, resuscitated cardiopulmonary arrest or stroke, in patients treated with colchicine after AMI.
Despite the cardiovascular benefit demonstrated in high-risk patients, little is known about the pathophysiological mechanisms involved, being the subject of debates about whether the observed results would be related to the reduction of the progression of atheroscletotic disease, to an antiplatelet effect, or both.
Primary objective: To evaluate the effect of colchicine in low dose for 30 ± 3 days on platelet aggregation by MultiplateTRAP.
Secondary objectives Evaluate the primary objective of the study using Multiplate ADP, ASPI and Collagen.
Exploratory Analysis
Comparison between the colchicine and placebo groups at the end of the 30 ± 3-day follow-up of the following parameters:
* Ultra-sensitive reactive C protein (hs-CRP);
* Interleukin 6 (IL-6);
* Interleukin 1 (IL-1);
* Serum Tromboxane B2;
* Count and fraction of reticulated platelets;
* Mean platelet volume (MPV);
* Total cholesterol / HDL / LDL / triglycerides, apolipoprotein A1, apolipoprotein B;
* Analysis of vascular reactivity;
* Transfer of lipids to HDL.
Analyze the primary outcome of the study in the following subgroups:
* Female versus male;
* Age group ( equal or major to 65 years);
* Presence or not of diabetes mellitus (characterized by use of hypoglycemic drugs previously and / or exam prior to randomization with HbA1c equal or minor to 6.5%);
* LVEF equal or major 40%;
* Obese versus non-obese (BMI equal or major 30)
* Smoker versus non-smoker
* median LDL
* PCRus equal or major 2mg / dl
Study design: Prospective, randomized, double-blind, placebo-controlled study. Patients with proven chronic coronary artery disease, documented by previous history of AMI, will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days. Randomization will be performed in 2 blocks of 40 patients at a rate of 1: 1. Blood samples will be obtained at the baseline visit and at the end-of-follow-up visit (30 ± 3days after the baseline visit).
Inclusion criteria: Agreement to sign a free and informed consent form; age ≥ 18 years; patients with previous acute myocardial infarction (or more than 1 year according to the criteria of the 4th universal definition using ASA 100mg / day.
Exclusion criteria: Use of any antithrombotic therapy other than AAS for less than 1 week; Stroke in the last 3 months; active infection or current use of systemic antimicrobial therapy; neoplasia in the last 3 years; inflammatory bowel disease or chronic diarrhea; hematological abnormality (Hb ≤ 11g / dL or\> 17g / dL, leukocytes ≤ 4,500 / mm3 or\> 11,000 / mm3, platelet count \<150,000 / mm3 or\> 450,000 / mm3); chronic kidney disease (estimated glomerular filtration rate \<30 ml / min / 1.73 m2) using the MDRD formula; liver disease defined by CHILD B or C; drug or alcohol abuse; dementia, psychiatric or any condition that, in the researcher's opinion, prevents participation and follow-up in the protocol; history of allergy to colchicine; current treatment with systemic corticosteroids or immunosuppressants.
Sample calculation: In a prior study, published in 2020, it was found an average platelet aggregability by Multiplate-TRAP in patients with chronic coronary disease of 102 AUC +/- 26. Another study analyzing platelet aggregation in vitro in healthy volunteers, found a reduction in aggregability by ADP by 40%. In the present study, for a hypothesis of superiority with a 20% reduction in the mean platelet aggregation in favor of colchicine over placebo, considering an alpha = 0.05 (two-tailed) and a power = 90%, the calculated sample size is 70 patients (35 per group), with a total of 80 being included to compensate for possible losses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Platelet Aggregation, Spontaneous
Coronary Artery Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Prospective, randomized, double-blind, placebo-controlled study.
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
DOUBLE
Participants
Investigators
Double-blind
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
Colchicine 0.5 mg QD
Group Type
EXPERIMENTAL
Colchicine 0.5 MG
Intervention Type
DRUG
Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
Placebo group
Placebo
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colchicine 0.5 MG
Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
Intervention Type
DRUG
Placebo
Patients with proven chronic coronary disease (documented by a previous history of AMI with or without ST-segment elevation) will be randomized to receive colchicine 0.5 mg once daily (intervention group) or placebo (control group) for a period of 30 ± 3 days.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Agreement to sign a free and informed consent form (ICF);
* Age equal or major18 years;
* Patients with previous acute myocardial infarction (for more than 1 year) according to the criteria of the 4th universal definition using ASA 100mg / day.
* Age equal or major18 years;
* Patients with previous acute myocardial infarction (for more than 1 year) according to the criteria of the 4th universal definition using ASA 100mg / day.
Exclusion Criteria
* Use of any antithrombotic therapy other than AAS for less than 1 week;
* Stroke in the last 3 months;
* Active infection or current use of systemic antimicrobial therapy;
* Neoplasia in the last 3 years;
* Inflammatory bowel disease or chronic diarrhea;
* Hematological abnormality (Hb equal or minor to11 g / dL or major to17g / dL, Leukocytes minor or equal 4,500 / mm3 or major 11,000 / mm3, platelet count minor 150,000 / mm3 or major450,000 / mm3);
* Chronic kidney disease (estimated glomerular filtration rate \<30 ml / min / 1.73 m2) using the MDRD17 formula;
* Liver disease defined by CHILD B or C; 18,19
* Abuse of drugs or alcohol;
* Dementia, psychiatric or any condition that, in the opinion of the researcher, prevents participation and follow-up in the protocol;
* History of allergy to colchicine;
* Current treatment with systemic corticosteroids or immunosuppressants.
* Stroke in the last 3 months;
* Active infection or current use of systemic antimicrobial therapy;
* Neoplasia in the last 3 years;
* Inflammatory bowel disease or chronic diarrhea;
* Hematological abnormality (Hb equal or minor to11 g / dL or major to17g / dL, Leukocytes minor or equal 4,500 / mm3 or major 11,000 / mm3, platelet count minor 150,000 / mm3 or major450,000 / mm3);
* Chronic kidney disease (estimated glomerular filtration rate \<30 ml / min / 1.73 m2) using the MDRD17 formula;
* Liver disease defined by CHILD B or C; 18,19
* Abuse of drugs or alcohol;
* Dementia, psychiatric or any condition that, in the opinion of the researcher, prevents participation and follow-up in the protocol;
* History of allergy to colchicine;
* Current treatment with systemic corticosteroids or immunosuppressants.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jose Carlos Nicolau
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Heart Institute (InCor) / University of São Paulo
São Paulo, São Paulo, Brazil
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Brazil
References
Explore related publications, articles, or registry entries linked to this study.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95. doi: 10.1056/NEJMra043430. No abstract available.
Reference Type
BACKGROUND
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.
Reference Type
BACKGROUND
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
Reference Type
BACKGROUND
Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ; CIRT Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 Feb 21;380(8):752-762. doi: 10.1056/NEJMoa1809798. Epub 2018 Nov 10.
Reference Type
BACKGROUND
Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010 Feb 24;303(8):754-62. doi: 10.1001/jama.2010.181.
Reference Type
BACKGROUND
Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013 Aug 17;382(9892):614-23. doi: 10.1016/S0140-6736(13)61170-8. Epub 2013 Jul 26.
Reference Type
BACKGROUND
Imazio M, Brucato A, Cemin R, Ferrua S, Maggiolini S, Beqaraj F, Demarie D, Forno D, Ferro S, Maestroni S, Belli R, Trinchero R, Spodick DH, Adler Y; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013 Oct 17;369(16):1522-8. doi: 10.1056/NEJMoa1208536. Epub 2013 Aug 31.
Reference Type
BACKGROUND
Corps AN, Hesketh TR, Metcalfe JC. Limitations on the use of phenothiazines and local anaesthetics as indicators of calmodulin function in intact cells. FEBS Lett. 1982 Feb 22;138(2):280-4. doi: 10.1016/0014-5793(82)80461-4. No abstract available.
Reference Type
BACKGROUND
Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004 Mar 11;428(6979):198-202. doi: 10.1038/nature02393.
Reference Type
BACKGROUND
Perico N, Ostermann D, Bontempeill M, Morigi M, Amuchastegui CS, Zoja C, Akalin E, Sayegh MH, Remuzzi G. Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation. J Am Soc Nephrol. 1996 Apr;7(4):594-601. doi: 10.1681/ASN.V74594.
Reference Type
BACKGROUND
Pope RM, Tschopp J. The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum. 2007 Oct;56(10):3183-8. doi: 10.1002/art.22938. No abstract available.
Reference Type
BACKGROUND
Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 Mar 9;440(7081):237-41. doi: 10.1038/nature04516. Epub 2006 Jan 11.
Reference Type
BACKGROUND
Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine. 2006 Dec;73(6):672-8. doi: 10.1016/j.jbspin.2006.03.006. Epub 2006 Sep 1.
Reference Type
BACKGROUND
Cimmino G, Tarallo R, Conte S, Morello A, Pellegrino G, Loffredo FS, Cali G, De Luca N, Golino P, Trimarco B, Cirillo P. Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascul Pharmacol. 2018 Dec;111:62-70. doi: 10.1016/j.vph.2018.09.004. Epub 2018 Oct 1.
Reference Type
BACKGROUND
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013 Jan 29;61(4):404-410. doi: 10.1016/j.jacc.2012.10.027. Epub 2012 Dec 19.
Reference Type
BACKGROUND
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16.
Reference Type
BACKGROUND
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018 Nov 13;138(20):e618-e651. doi: 10.1161/CIR.0000000000000617. No abstract available.
Reference Type
BACKGROUND
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70. doi: 10.7326/0003-4819-130-6-199903160-00002.
Reference Type
BACKGROUND
Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1-85. No abstract available.
Reference Type
BACKGROUND
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646-9. doi: 10.1002/bjs.1800600817. No abstract available.
Reference Type
BACKGROUND
Arantes FBB, Menezes FR, Franci A, Barbosa CJDG, Dalcoquio TF, Nakashima CAK, Baracioli LM, Furtado RHM, Nomelini QSS, Ramires JAF, Kalil Filho R, Nicolau JC. Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial. Adv Ther. 2020 Jan;37(1):420-430. doi: 10.1007/s12325-019-01153-8. Epub 2019 Nov 22.
Reference Type
BACKGROUND
von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A. [Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate]. Hamostaseologie. 2007 Aug;27(3):155-60; quiz 161-2. doi: 10.1007/978-3-540-36715-4_49. German.
Reference Type
BACKGROUND
Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schomig A, Kastrati A, von Beckerath N. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost. 2008 Jan;99(1):121-6. doi: 10.1160/TH07-07-0478.
Reference Type
BACKGROUND
Lo Prete AC, Dina CH, Azevedo CH, Puk CG, Lopes NH, Hueb WA, Maranhao RC. In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment. Lipids. 2009 Oct;44(10):917-24. doi: 10.1007/s11745-009-3342-2. Epub 2009 Sep 16.
Reference Type
BACKGROUND
Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, Karas RH, Udelson JE. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J. 2003 Jul;146(1):168-74. doi: 10.1016/S0002-8703(03)00094-2.
Reference Type
BACKGROUND
Hamburg NM, Benjamin EJ. Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med. 2009 Jan;19(1):6-11. doi: 10.1016/j.tcm.2009.03.001.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SDC:5007/20/036
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Clopidogrel Efficacy and Acute Coronary Syndromes
NCT00839267
COMPLETED
Prasugrel Re-load Strategies
NCT01201772
COMPLETED
PHASE4
Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention
NCT06095765
RECRUITING
PHASE3
Evaluation of Platelet Aggregability in Patients With Previous Acute Myocardial Infarction or Concomitant Lower Extremity Peripheral Artery Disease
NCT06454045
ACTIVE_NOT_RECRUITING
Platelet Reactivity in Stent Thrombosis Patients
NCT01012544
COMPLETED
PHASE4
Effect of Clopidogrel Loading and Risk of PCI
NCT00457236
UNKNOWN
Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects
NCT01129271
COMPLETED
PHASE1
Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event
NCT00356135
COMPLETED
PHASE2
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
NCT01260584
COMPLETED
PHASE4
Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention
NCT01505790
COMPLETED
PHASE3
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
NCT01107899
TERMINATED
PHASE1
Platelet Reactivity After Receiving Clopidogrel Among Moderate CKD Patients Undergoing PCI
NCT02556671
UNKNOWN
Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function
NCT00693069
COMPLETED
PHASE3
The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization
NCT00644657
COMPLETED
NA
Residual Inflammatory Risk-Guided colcHicine in Elderly Trial
NCT06025071
NOT_YET_RECRUITING
PHASE4
Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome
NCT01774838
COMPLETED
PHASE3
A Study to Assess the Effect of SB 659032 on Platelet Function
NCT01750827
COMPLETED
PHASE1
Platelet Reactivity And Clinical ThrombotIC Events Study
NCT03525145
UNKNOWN
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
NCT00386191
COMPLETED
PHASE4
Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT)
NCT04848857
COMPLETED
PHASE4
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization
NCT03953547
COMPLETED
The Correlation Between Genetic Polymorphism, Platelet Activity, Clopidogrel Responsiveness, and Serum Adipokine Concentration in Asian Acute Coronary Syndrome Patients
NCT01255267
UNKNOWN
Evaluation of Platelet Function After Statin Loading Dose in Patients Before Percutaneous Coronary Intervention
NCT01526460
COMPLETED
PHASE2
Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI
NCT00889044
UNKNOWN
PHASE3
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
NCT01107912
COMPLETED
PHASE1